SHANGHAI , June 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK ), an innovation-driven biopharmaceutical company with a fully integrated industry chain, presented two latest clinical study results of its independently developed Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) in cervical cancer at the European Society for Medical Oncology Gynaecological Cancers Congress 2026 (ESMO Gynae 2026) in Copenhagen, Denmark, held June 17–19, 2026. The two studies demonstrated that 9MW282